Ticker Details
CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
IPO Date:	October 8, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$714.71M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.26 | 3.52%
Avg Daily Range (30 D):	$0.10 | 2.90%
Avg Daily Range (90 D):	$0.11 | 2.94%

Institutional Daily Volume
Avg Daily Volume:	1.15M
Avg Daily Volume (30 D):	2.3M
Avg Daily Volume (90 D):	2.97M

Trade Size
Avg Trade Size (Sh.):	195
Avg Trade Size (Sh.) (30 D):	154
Avg Trade Size (Sh.) (90 D):	165

Institutional Trades
Total Institutional Trades:	1,281
Avg Institutional Trade:	$1.61M
Avg Institutional Trade (30 D):	$1.36M
Avg Institutional Trade (90 D):	$2.27M
Avg Institutional Trade Volume:	.29M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.83M
Avg Closing Trade (30 D):	$1.46M
Avg Closing Trade (90 D):	$2.49M
Avg Closing Volume:	313.14K

News

Jun 3, 2026 @ 12:00 PM CytomX Announces Expansion of Strategic Research C... Source: Na

May 21, 2026 @ 12:00 PM CytomX Therapeutics to Present at Upcoming June In... Source: Not Specified

Apr 22, 2026 @ 10:28 PM Small Cap or Megacap: Which Healthcare Stock Is Ri... Source: Jack Delaney

Mar 18, 2026 @ 2:46 AM CytomX Therapeutics Announces Pricing of $250 Mill... Source: Cytomx Therapeutics, Inc.

Feb 4, 2026 @ 1:00 PM CytomX Therapeutics to Present at Upcoming Februar... Source: Not Specified

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS
Diluted EPS
Revenue	$1.42M	$10.26M	$.66M
Gross Profit
Net Income / Loss	$-20.67M	$-18.25M	$-26.51M
Operating Income / Loss	$-23.78M	$-19.67M	$-27.93M
Cost of Revenue
Net Cash Flow	$-11.6M	$16.16M	$-21.02M
PE Ratio